Maria Birlem
CEO

This company develops and operates in-house space labs and ground simulators to conduct biotechnology research in microgravity environments. They enable customers to advance cell culture growth, disease modeling, protein crystallization, and synthetic biology applications beyond Earth's gravity. Yuri provides access to space-based experimentation to foster innovation in life sciences and materials research.
Raised to date
$2.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.




Terrestrial research environments limit the development of complex 3D cell cultures and the analysis of biomolecular structures due to the effects of gravity on cellular development, fluid dynamics, and crystallization processes. These limitations hinder advancements in drug development, cell-based therapies, and the understanding of disease mechanisms.
Yuri provides hardware and services for conducting life science research in microgravity, enabling the growth of complex 3D cell cultures and the analysis of biomolecular structures. By leveraging the unique conditions of space, Yuri facilitates advancements in drug development, cell-based therapies, and synthetic biology. Their offerings allow researchers to overcome the limitations of terrestrial environments, such as gravitational forces that restrict cell development and affect fluid dynamics. Yuri's solutions support a range of applications, including modeling human diseases, studying plant biology, and advancing nanofluidics.
Yuri's primary customers include biotech companies, pharmaceutical firms, research institutions, and government agencies involved in drug development, cell-based therapies, and space-based research.